Myriad Genetics Shares Rise 5.9% on Launch of Breast Cancer MRD Test
Shares jumped 5.9% after the company launched its Precise MRD test for breast cancer and presented at the TD Cowen Health Care Conference, with initial rollout to select oncology practices and nationwide expansion planned later this year. The company also reaffirmed its full-year 2026 financial outlook, signalling management confidence.
1. Launch of Precise MRD test
The company introduced the Precise MRD test for breast cancer patients, a molecular residual disease detection tool, with initial deployment at select oncology practices and plans for nationwide commercial rollout later this year.
2. Healthcare conference presentation
Management presented the new test data at the TD Cowen 46th Annual Health Care Conference, highlighting its diagnostic accuracy and potential to enhance patient monitoring during treatment.
3. Stock performance and outlook
Shares rose 5.9% before settling at $5.26, up 4.9% from the prior close, as the company reaffirmed its full-year 2026 financial outlook despite a 14.4% year-to-date decline and trading 50% below its 52-week high.